Matches in SemOpenAlex for { <https://semopenalex.org/work/W4235513222> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4235513222 endingPage "65" @default.
- W4235513222 startingPage "60" @default.
- W4235513222 abstract "At TBI there are disturbances in activity of immune system, can complicate regenerative and reparative responses in a brain. The aim of the study was to study the content of CD-16 cells in the spleen and brain parenchyma at different times after TBI in rats and in the correction of disorders in their composition by immunomodulatory drug galalite.Methods. Craniocerebral trauma in animals was modeled by dropping a load weighing 100 g from a height of 120 cm on the head of rats that were anesthetized and were in a state of narcotic sleep, which lasted up to 30 minutes. To correct the resulting disorders used immunomodulatory drug galavit at a dose of 2 mg / kg of animal weight in a volume of0.5 ml, which was administered intramuscularly to animals for 2, 3, 4 days after injury. The spleen and the left and right hemispheres of the brain were homogenized in 5.0 ml of medium 199 and suspensions containing 10.0x106 cells per 1 ml of medium 199 microglia were prepared and infiltrated CNS monocytes were prepared by the method of Sedgwick J. in co-authors. Determination of the level of CD-16 cells in suspensions of spleen and microglia was performed on a flow cytometer using monoclonal antibodies against CD-16 receptor company BD Biosciences according to the instructions for antibodies.Results. In mild TBI in rats, the number of CD- 16 cells containing the FcR III receptor decreases in the spleen for 2 to 5 days, and the number of these cells in the fractions of microglial cells increases. Galavit is a drug with immunomodulatory properties, has virtually no effect on low levels of CD-16 cells in the spleen and stimulates their accumulation in the brain for 10 days after TBI.Conclusions. The results indicate the effect of Galavit on the level of CD-16 cells in the spleen and brain, which indicates the immunomodulatory activity of this drug." @default.
- W4235513222 created "2022-05-12" @default.
- W4235513222 creator A5044490086 @default.
- W4235513222 creator A5063674961 @default.
- W4235513222 creator A5070178416 @default.
- W4235513222 creator A5087235202 @default.
- W4235513222 date "2020-07-29" @default.
- W4235513222 modified "2023-09-28" @default.
- W4235513222 title "CHANGES IN THE CONTENT OF IMMUNE CELLS CONTAINING THE FcR III RECEPTOR IN THE SLEEP AND BRAIN AFTER EXPERIMENTAL TBI" @default.
- W4235513222 doi "https://doi.org/10.37321/immunology.2020.02-06" @default.
- W4235513222 hasPublicationYear "2020" @default.
- W4235513222 type Work @default.
- W4235513222 citedByCount "0" @default.
- W4235513222 crossrefType "journal-article" @default.
- W4235513222 hasAuthorship W4235513222A5044490086 @default.
- W4235513222 hasAuthorship W4235513222A5063674961 @default.
- W4235513222 hasAuthorship W4235513222A5070178416 @default.
- W4235513222 hasAuthorship W4235513222A5087235202 @default.
- W4235513222 hasBestOaLocation W42355132221 @default.
- W4235513222 hasConcept C118552586 @default.
- W4235513222 hasConcept C126322002 @default.
- W4235513222 hasConcept C142724271 @default.
- W4235513222 hasConcept C159654299 @default.
- W4235513222 hasConcept C170493617 @default.
- W4235513222 hasConcept C185592680 @default.
- W4235513222 hasConcept C196822366 @default.
- W4235513222 hasConcept C203014093 @default.
- W4235513222 hasConcept C2775849661 @default.
- W4235513222 hasConcept C2776914184 @default.
- W4235513222 hasConcept C2779830541 @default.
- W4235513222 hasConcept C2780931953 @default.
- W4235513222 hasConcept C2781017439 @default.
- W4235513222 hasConcept C42219234 @default.
- W4235513222 hasConcept C542903549 @default.
- W4235513222 hasConcept C71924100 @default.
- W4235513222 hasConcept C8891405 @default.
- W4235513222 hasConcept C98274493 @default.
- W4235513222 hasConceptScore W4235513222C118552586 @default.
- W4235513222 hasConceptScore W4235513222C126322002 @default.
- W4235513222 hasConceptScore W4235513222C142724271 @default.
- W4235513222 hasConceptScore W4235513222C159654299 @default.
- W4235513222 hasConceptScore W4235513222C170493617 @default.
- W4235513222 hasConceptScore W4235513222C185592680 @default.
- W4235513222 hasConceptScore W4235513222C196822366 @default.
- W4235513222 hasConceptScore W4235513222C203014093 @default.
- W4235513222 hasConceptScore W4235513222C2775849661 @default.
- W4235513222 hasConceptScore W4235513222C2776914184 @default.
- W4235513222 hasConceptScore W4235513222C2779830541 @default.
- W4235513222 hasConceptScore W4235513222C2780931953 @default.
- W4235513222 hasConceptScore W4235513222C2781017439 @default.
- W4235513222 hasConceptScore W4235513222C42219234 @default.
- W4235513222 hasConceptScore W4235513222C542903549 @default.
- W4235513222 hasConceptScore W4235513222C71924100 @default.
- W4235513222 hasConceptScore W4235513222C8891405 @default.
- W4235513222 hasConceptScore W4235513222C98274493 @default.
- W4235513222 hasIssue "2" @default.
- W4235513222 hasLocation W42355132221 @default.
- W4235513222 hasOpenAccess W4235513222 @default.
- W4235513222 hasPrimaryLocation W42355132221 @default.
- W4235513222 hasRelatedWork W13801119 @default.
- W4235513222 hasRelatedWork W1906851 @default.
- W4235513222 hasRelatedWork W2318811 @default.
- W4235513222 hasRelatedWork W3994596 @default.
- W4235513222 hasRelatedWork W4353681 @default.
- W4235513222 hasRelatedWork W5109800 @default.
- W4235513222 hasRelatedWork W7442663 @default.
- W4235513222 hasRelatedWork W796493 @default.
- W4235513222 hasRelatedWork W8149189 @default.
- W4235513222 hasRelatedWork W917114 @default.
- W4235513222 isParatext "false" @default.
- W4235513222 isRetracted "false" @default.
- W4235513222 workType "article" @default.